Lemaitre Vasculr Stock Price, News & Analysis

LeMaitre Vascular reported strong Q1 2025 financial results with sales reaching $59.9 million, up 12% (13% organic). The company achieved a gross margin of 69.2% and operating income of $12.6 million, up 6%. Earnings per share increased 10% to $0.48. Growth was driven by grafts (+17%) and carotid shunts (+14%), with EMEA sales up 18%. The company announced a $0.20 quarterly dividend and increased its 2025 guidance, now expecting sales of $245 million (+12%) and EPS of $2.16 (+12%). Notably, Artegraft received MDR CE Mark approval, enabling European market expansion. The company maintains a strong cash position of $302.5 million and has authorized a $75 million share repurchase program.

LeMaitre Vascular (NASDAQ:LMAT) has scheduled its first quarter 2025 financial results announcement for Thursday, May 1, 2025, after market close. The company will host a conference call at 5:00 PM EDT on the same day to discuss quarterly results, business highlights, and future outlook. Interested participants can access the live call by registering online, after which they will receive dial-in information and a PIN. Additionally, an audio webcast will be available both live and for replay through the company's investor relations website.

LeMaitre Vascular (Nasdaq: LMAT) has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The company's management team is scheduled to deliver their presentation on Tuesday, April 8, 2025, at 3:45 PM EDT. This virtual event represents an opportunity for investors and healthcare industry stakeholders to gain insights into LeMaitre's operations and strategic initiatives.

LeMaitre Vascular (Nasdaq:LMAT) has announced its management team's participation in three major investor conferences this March 2025:

• The 37th Annual ROTH Conference on March 17 at The Laguna Cliffs Marriott in Dana Point, CA, with a presentation scheduled for 4:00 PM PDT
• The KeyBanc Healthcare Forum, a virtual event on March 19, presenting at 1:30 PM EDT
• The Oppenheimer 35th Annual Healthcare MedTech & Services Conference, another virtual event on March 20, with a presentation time of 10:00 AM EDT

LeMaitre (LMAT) reported strong Q4 2024 financial results with sales reaching $55.7 million, up 14% year-over-year. The company demonstrated robust performance with operating income increasing 26% to $12.9 million and earnings per diluted share growing 30% to $0.49.

Key growth drivers included grafts (+23%), carotid shunts (+14%), and catheters (+12%). Regional sales showed strong momentum with APAC up 21%, EMEA 18%, and Americas 12%. Gross margin improved to 69.3%, up 121 basis points from Q4 2023.

The company announced significant financial moves, including a 25% increase in quarterly dividend to $0.20/share, issuance of $172.5 million in Convertible Senior Notes due 2030, and authorization of a $75 million share repurchase program. Cash position strengthened to $299.7 million. Additionally, XenoSure patches received Chinese cardiac approval in December.

LeMaitre Vascular (LMAT) has scheduled its Q4 2024 earnings release for Thursday, February 27, 2025, after market close. The company will host a conference call at 5:00 PM EST on the same day to discuss financial results, business highlights, and company outlook. Interested parties can access the live call by registering online, and all registrants will receive dial-in information and a PIN. Additionally, an audio webcast will be available live and for replay through the company's investor relations website.

LeMaitre Vascular (Nasdaq: LMAT) has announced the pricing of $150 million in 2.50% Convertible Senior Notes due 2030. The notes will be sold to qualified institutional buyers with settlement scheduled for December 19, 2024. The company granted initial purchasers an option to buy an additional $22.5 million in notes.

The notes will accrue interest at 2.50% annually, payable semi-annually, and mature on February 1, 2030. The initial conversion rate is 8.3521 shares per $1,000 principal amount, representing a conversion price of $119.73 per share - a 30% premium over the current stock price of $92.10. The net proceeds, estimated at $145.9 million (or $167.8 million if additional notes are purchased), will be used for working capital and general purposes, including potential acquisitions.

LeMaitre Vascular (LMAT) announced plans to offer $150 million in Convertible Senior Notes due 2030, with an additional $22.5 million option for initial purchasers. The notes will be senior, unsecured obligations with semi-annual interest payments, convertible into cash, LMAT common stock, or a combination at LeMaitre's discretion.

The notes will be redeemable after February 5, 2028, if LMAT's stock price exceeds 130% of the conversion price. Noteholders can require LeMaitre to repurchase notes if fundamental changes occur. The company plans to use proceeds for working capital and general purposes, including potential acquisitions. The offering is to qualified institutional buyers under Rule 144A.

LeMaitre Vascular (Nasdaq:LMAT) has announced its participation in two major investor conferences this December. David Roberts, President, will present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 3:30 PM EST in New York City. Additionally, he will present at the Stifel "MedTech Madness" West Coast Bus Tour on December 12, 2024, at 11:45 AM PST in Menlo Park, California.